Logo image of BCAX

BICARA THERAPEUTICS INC (BCAX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCAX - US0554771032 - Common Stock

18.88 USD
+0.84 (+4.66%)
Last: 11/24/2025, 8:00:00 PM
18.88 USD
0 (0%)
After Hours: 11/24/2025, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BCAX. BCAX was compared to 533 industry peers in the Biotechnology industry. While BCAX has a great health rating, there are worries on its profitability. BCAX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BCAX had negative earnings in the past year.
In the past year BCAX has reported a negative cash flow from operations.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -28.61%, BCAX is doing good in the industry, outperforming 68.86% of the companies in the same industry.
BCAX has a better Return On Equity (-30.17%) than 77.67% of its industry peers.
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROIC N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 200 -200 -400

1.3 Margins

BCAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for BCAX has been increased compared to 1 year ago.
There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 25.58 indicates that BCAX is not in any danger for bankruptcy at the moment.
The Altman-Z score of BCAX (25.58) is better than 92.87% of its industry peers.
BCAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 25.58
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

BCAX has a Current Ratio of 14.14. This indicates that BCAX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BCAX (14.14) is better than 90.43% of its industry peers.
A Quick Ratio of 14.14 indicates that BCAX has no problem at all paying its short term obligations.
BCAX's Quick ratio of 14.14 is amongst the best of the industry. BCAX outperforms 90.43% of its industry peers.
Industry RankSector Rank
Current Ratio 14.14
Quick Ratio 14.14
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

BCAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -302.87%.
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 3.00% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.95%
EPS Next 2Y-1.06%
EPS Next 3Y-0.29%
EPS Next 5Y3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BCAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.06%
EPS Next 3Y-0.29%

More info and screens

0

5. Dividend

5.1 Amount

BCAX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BICARA THERAPEUTICS INC

NASDAQ:BCAX (11/24/2025, 8:00:00 PM)

After market: 18.88 0 (0%)

18.88

+0.84 (+4.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-24 2026-03-24
Inst Owners86.72%
Inst Owner Change2.3%
Ins Owners1.46%
Ins Owner Change-3.1%
Market Cap1.03B
Revenue(TTM)N/A
Net Income(TTM)-121.52M
Analysts82.67
Price Target33.22 (75.95%)
Short Float %14.69%
Short Ratio9.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.91%
Min EPS beat(2)-19.6%
Max EPS beat(2)13.77%
EPS beat(4)1
Avg EPS beat(4)-21.18%
Min EPS beat(4)-60.69%
Max EPS beat(4)13.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.64%
PT rev (3m)-1.79%
EPS NQ rev (1m)-19.08%
EPS NQ rev (3m)-19.73%
EPS NY rev (1m)0%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.56
P/tB 2.56
EV/EBITDA N/A
EPS(TTM)-2.24
EYN/A
EPS(NY)-2.71
Fwd EYN/A
FCF(TTM)-2.07
FCFYN/A
OCF(TTM)-2.07
OCFYN/A
SpS0
BVpS7.38
TBVpS7.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -28.61%
ROE -30.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-200.05%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.49%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.14
Quick Ratio 14.14
Altman-Z 25.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1710.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-302.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.13%
EPS Next Y11.95%
EPS Next 2Y-1.06%
EPS Next 3Y-0.29%
EPS Next 5Y3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-106.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.28%
EBIT Next 3Y-38.1%
EBIT Next 5YN/A
FCF growth 1Y-61.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.83%
OCF growth 3YN/A
OCF growth 5YN/A

BICARA THERAPEUTICS INC / BCAX FAQ

What is the ChartMill fundamental rating of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCAX.


What is the valuation status for BCAX stock?

ChartMill assigns a valuation rating of 0 / 10 to BICARA THERAPEUTICS INC (BCAX). This can be considered as Overvalued.


How profitable is BICARA THERAPEUTICS INC (BCAX) stock?

BICARA THERAPEUTICS INC (BCAX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for BCAX stock?

The Earnings per Share (EPS) of BICARA THERAPEUTICS INC (BCAX) is expected to grow by 11.95% in the next year.